WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients
Clinical trial NCT06691308 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06691308
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-12
- Primary completion
- 2027-05-31
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.